Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$27,000.00

Host-directed therapeutics to combat drug-resistant Salmonella.

FY 2024-25

Summary
Salmonella infections are typically associated with food poisoning causing a few days of diarrhea that often resolves on its own. A strain of Salmonella has recently emerged in Africa, ST313, which manifests as a fever with a bloodstream infection that is highly resistant to antibiotics. Our body's first line of defense, the innate immune system, can fight off many pathogens before we know we are ill. However, Salmonella has evolved to evade this system by masking itself and neutralizing the host natural defense systems from inside the cells. The intracellular nature of this pathogen combined with ST313 extensive antibiotic resistance limits the available treatments for those with the disease. An alternative treatment to conventional antibiotics are host-directed therapeutics. These compounds strengthen the innate immune response rather than target the bacteria directly. Previous work has identified potential host-directed compounds that are effective against drug-resistant Salmonella. My project seeks to expand our knowledge on how ST313 is overcoming host immunity and how we can re-sensitize it to innate immune killing with the use of host-directed therapeutics. I hypothesize that the characterization of host-directed compounds will reveal the host cell pathways involved in controlling intracellular Salmonella replication. Using genomics technology to profile how these compounds are acting on our immune cells will provide entry points for new drug discovery to overcome drug-resistant infections. In addition, I will be examining the response of ST313 to this boosted immune state to probe for weaknesses in its defense repertoire.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530109
Name
Lange Victoria V
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Host-directed therapeutics to combat drug-resistant Salmonella.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Resistance; Bacterial Pathogenicity; Host-Directed Therapeutics; Host-Pathogen Interaction; Innate Immune System; Macrophage; Salmonella; Virulence Factors
Abstract
Salmonella infections are typically associated with food poisoning causing a few days of diarrhea that often resolves on its own. A strain of Salmonella has recently emerged in Africa, ST313, which manifests as a fever with a bloodstream infection that is highly resistant to antibiotics. Our body's first line of defense, the innate immune system, can fight off many pathogens before we know we are ill. However, Salmonella has evolved to evade this system by masking itself and neutralizing the host natural defense systems from inside the cells. The intracellular nature of this pathogen combined with ST313 extensive antibiotic resistance limits the available treatments for those with the disease. An alternative treatment to conventional antibiotics are host-directed therapeutics. These compounds strengthen the innate immune response rather than target the bacteria directly. Previous work has identified potential host-directed compounds that are effective against drug-resistant Salmonella. My project seeks to expand our knowledge on how ST313 is overcoming host immunity and how we can re-sensitize it to innate immune killing with the use of host-directed therapeutics. I hypothesize that the characterization of host-directed compounds will reveal the host cell pathways involved in controlling intracellular Salmonella replication. Using genomics technology to profile how these compounds are acting on our immune cells will provide entry points for new drug discovery to overcome drug-resistant infections. In addition, I will be examining the response of ST313 to this boosted immune state to probe for weaknesses in its defense repertoire.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lange, Victoria V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~